Supplemental Financial Information (Tables)

12 Months Ended

Dec. 31, 2023

Balance Sheet Related Disclosures [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment, net consisted of the following (in thousands):

	December 31, 2023			December 31, 2022
Leasehold improvements	$	2,117		$	2,091
Laboratory equipment		2,868			2,868
Computer equipment		1,133			1,115
Furniture and fixtures		864			898
Construction in progress		6,823			9,633
		13,805			16,605
Accumulated depreciation		(2,979	)		(1,642	)
Property, plant and equipment, net	$	10,826		$	14,963

Schedule of Accrued Expenses and Other Current Labilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	December 31, 2023		December 31, 2022
Accrued research and development	$	3,467	$	8,190
Accrued compensation		3,423		2,519
Accrued clinical trial		1,851		1,473
Lease liabilities, current portion		1,646		1,521
Warrant liability		454		—
Accrued severance		390		1,463
Accrued professional and consulting fees		330		390
Accrued property, plant and equipment		—		2,081
Other		723		650
Total accrued expenses and other current liabilities	$	12,284	$	18,287

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	December 31, 2023		December 31, 2022
Prepaid research and development	$	1,412	$	4,840
Prepaid clinical trial		802		2,119
Deferred offering costs		681		724
Prepaid insurance		292		388
Other		292		466
Total prepaid expenses and other current assets	$	3,479	$	8,537